AMGN241206P277500
- 3.10
- +0.75+31.91%
Amgen Newsroom
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
Deutsche Bank lowered amgen's target price to $285.
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
RBC Capital lowers Amgen's target price to $330.
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating
Citigroup Adjusts Price Target on Amgen to $310 From $335, Neutral Rating Maintained
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Sticks to Their Buy Rating for Amgen (AMGN)
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
Amgen Initiated at Peer Perform by Wolfe Research